Oncosem Onkolojik Sistemlernayi ve Ticaret ASIST:ONCSM 80 ROC (Joel Greenblatt) % is 26.20% as of Mar. 2026, which is 200% above its 10-year median of 8.72. GuruFocus rates IST:ONCSM with a GF Score™ of 80/100 and a GF Value™ of ₺253.18 (Fairly Valued). The stock has 4 warning signs investors should review. Among 841 Medical Devices & Instruments companies, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks better than 79.67% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 26.20%.
IST:ONCSM's ROC (Joel Greenblatt) % is ranked better than 79.67% of 841
companies
in the Medical Devices & Instruments industry
Industry Median: 3.94
vs IST:ONCSM: 28.78
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROC (Joel Greenblatt) % Chart
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Annual Data
IST:ONCSM vs ABT, SYK, MDT: ROC (Joel Greenblatt) % Comparison
For the Medical Devices subindustry, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROC (Joel Greenblatt) % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROC (Joel Greenblatt) % falls into.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 26.20% mean?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) has a ROC (Joel Greenblatt) % of 26.20% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. This is 200% above median its historical median of 8.72. According to the industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #171 out of 841 companies in the Medical Devices & Instruments industry, placing it in the top 20.3%.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROC (Joel Greenblatt) % too high?
Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current ROC (Joel Greenblatt) % of 26.20% is 200% above median its 10-year median of 8.72. The Medical Devices & Instruments industry median ROC (Joel Greenblatt) % is 3.94. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 26.20% is 565% above this industry median. Based on the distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #171 out of 841 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Oncosem Onkolojik Sistemlernayi ve Ticaret AS's ROC (Joel Greenblatt) % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Oncosem Onkolojik Sistemlernayi ve Ticaret AS ranks #171 out of 841 companies for ROC (Joel Greenblatt) %. This places Oncosem Onkolojik Sistemlernayi ve Ticaret AS in the top 20% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 3.94. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's value of 26.20% is 565% above this benchmark. While the company's 10-year median is 8.72 vs. the industry median of 3.94, Oncosem Onkolojik Sistemlernayi ve Ticaret AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Medical Devices & Instruments company?
The median ROC (Joel Greenblatt) % among Medical Devices & Instruments companies is 3.94, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current ROC (Joel Greenblatt) % of 26.20% is 565% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Oncosem Onkolojik Sistemlernayi ve Ticaret AS and its competitors. For the Medical Devices & Instruments industry, the median ROC (Joel Greenblatt) % is 3.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's current ROC (Joel Greenblatt) % is 26.20%, which is 200% above median its own 10-year median of 8.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock overvalued right now?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) is currently considered Fairly Valued. The stock's GF Value™ is ₺253.18, compared to a current price of ₺250.50 — trading 1.1% below its estimated fair value. The current ROC (Joel Greenblatt) % is 26.20%, which is 200% above median its 10-year median of 8.72 and 565% above the Medical Devices & Instruments industry median of 3.94. Oncosem Onkolojik Sistemlernayi ve Ticaret AS's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM), the current ROC (Joel Greenblatt) % is 26.20% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Oncosem Onkolojik Sistemlernayi ve Ticaret AS (IST:ONCSM) Overvalued in 2026?
Based on GuruFocus' analysis, Oncosem Onkolojik Sistemlernayi ve Ticaret AS stock appears to be undervalued.
The current stock price of ₺250.50 is trading 1.1% below its estimated GF Value™ of ₺253.18.
GuruFocus considers Oncosem Onkolojik Sistemlernayi ve Ticaret AS to be Fairly Valued.
Key valuation signals for IST:ONCSM:
ROC (Joel Greenblatt) %: 26.20% (200% above median its 10-year median of 8.72)
GF Value™: ₺253.18 vs. price of ₺250.50 (1.1% below fair value)
Industry Position: 565% above the Medical Devices & Instruments median (#171 of 841)
No single metric tells the full story. See the IST:ONCSM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Oncosem Onkolojik Sistemlernayi ve Ticaret AS Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:ONCSM has been successfully added to your 
